Apolipoprotein B

Why This Matters

Among all the apolipoproteins, none is more important in preventive cardiology than apolipoprotein B (ApoB). Every lipoprotein capable of entering and becoming retained within the arterial wall carries exactly one molecule of ApoB. Because each atherogenic lipoprotein contains one ApoB molecule, measuring ApoB provides a direct estimate of the number of circulating atherogenic particles. This single fact is why this handbook — and the main chapters of this book — treat ApoB as the more informative number.

What Is Apolipoprotein B?

Apolipoprotein B is the principal structural protein of all atherogenic lipoproteins. It is essential for the formation, secretion, transport, and clearance of these particles.

Unlike many other apolipoproteins, ApoB remains permanently attached to the lipoprotein throughout its entire life cycle. It is not exchanged between particles and serves as the particle's permanent structural backbone. Every VLDL, IDL, LDL, and lipoprotein(a) particle contains one — and only one — molecule of ApoB.

ApoB Is a Marker of Particle Number

The relationship between ApoB and atherogenic lipoproteins makes it an excellent measure of particle concentration.

Because every atherogenic particle contains a single ApoB molecule, the ApoB concentration in plasma closely reflects the total number of circulating particles capable of entering the arterial wall.

This is an important distinction. LDL cholesterol measures the amount of cholesterol carried within LDL particles, whereas ApoB measures the number of atherogenic particles themselves.

Two individuals may have the same LDL cholesterol concentration but markedly different numbers of LDL particles. The individual with more particles has more opportunities for those particles to enter the arterial wall and contribute to atherosclerosis.

Which Lipoproteins Contain ApoB?

All potentially atherogenic lipoproteins contain ApoB.

These include chylomicron remnants, VLDL, IDL, LDL, and lipoprotein(a). Although these particles differ in size, lipid composition, and physiological function, they share one characteristic that unites them: each carries a single ApoB molecule.

For this reason, ApoB represents the total burden of circulating atherogenic lipoproteins rather than a single lipoprotein class.

ApoB and Atherosclerosis

Atherosclerosis is driven by the retention of ApoB-containing lipoproteins within the arterial wall.

As the number of circulating ApoB particles increases, so does the likelihood that these particles will enter the arterial intima and become retained. Once retained, they may undergo modification, trigger inflammation, and initiate the formation of atherosclerotic plaque.

The cumulative exposure of the arterial wall to ApoB-containing particles over many years is a major determinant of cardiovascular risk.

ApoB and LDL Cholesterol Are Not Always the Same

In many individuals, LDL cholesterol and ApoB provide similar information. However, they may become discordant when the cholesterol content of individual particles changes.

Conditions such as insulin resistance, obesity, type 2 diabetes mellitus, hypertriglyceridemia, and metabolic syndrome often produce smaller, cholesterol-depleted LDL particles. As a result, LDL cholesterol may appear satisfactory while the number of ApoB-containing particles remains elevated.

In these situations, ApoB provides a more accurate estimate of atherogenic particle burden than LDL cholesterol alone — and insulin resistance is precisely the condition most likely to create this kind of discordance, a link explored in depth later in this handbook and throughout this book's main chapters.

Clinical Relevance

A growing body of evidence demonstrates that ApoB predicts cardiovascular risk more accurately than LDL cholesterol in many clinical settings. A meta-analysis pooling more than 233,000 subjects across twelve independent studies found ApoB to be the strongest predictor of cardiovascular events among the three markers compared, outperforming both LDL cholesterol and non-HDL cholesterol.

The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines formally recognize ApoB as an important tool for risk assessment, particularly in patients with diabetes, metabolic syndrome, obesity, hypertriglyceridemia, or discordant lipid measurements.

Because most lipid-lowering therapies ultimately reduce the number of ApoB-containing particles, ApoB has also become a valuable marker for monitoring treatment response.

Clinical Pearls

• Every atherogenic lipoprotein contains one ApoB molecule.
• ApoB measures the number of circulating atherogenic particles.
• LDL cholesterol measures cholesterol mass, not particle number.
• ApoB and LDL cholesterol may become discordant.
• ApoB often provides a more accurate assessment of cardiovascular risk than LDL cholesterol alone.

Common Misconceptions

Misconception: LDL cholesterol and ApoB measure the same thing.

Reality: LDL cholesterol measures the amount of cholesterol carried within LDL particles, whereas ApoB measures the number of atherogenic lipoprotein particles.

Misconception: Only LDL contains ApoB.

Reality: ApoB is present on all potentially atherogenic lipoproteins, including VLDL, IDL, LDL, lipoprotein(a), and remnant lipoproteins.

Misconception: A normal LDL cholesterol level always indicates a low number of atherogenic particles.

Reality: In many individuals, particularly those with insulin resistance or hypertriglyceridemia, ApoB may remain elevated despite an apparently acceptable LDL cholesterol concentration.

Clinical Bottom Line

Apolipoprotein B is the most direct measure of the number of circulating atherogenic lipoproteins. Because each potentially atherogenic particle contains one ApoB molecule, ApoB provides a more accurate assessment of particle burden and, in many patients, a better estimate of cardiovascular risk than LDL cholesterol alone.